Home > Research > Publications & Outputs > 1561O The future of the oncology workforce sinc...

Links

Text available via DOI:

View graph of relations

1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series

Research output: Contribution to Journal/MagazineMeeting abstractpeer-review

Published

Standard

1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series. / Lim, K. H. J.; Hardy, Claire.
In: Annals of Oncology, Vol. 32 , No. Supplement 5, 21.09.2021, p. S1130-S1131.

Research output: Contribution to Journal/MagazineMeeting abstractpeer-review

Harvard

APA

Vancouver

Lim KHJ, Hardy C. 1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series. Annals of Oncology. 2021 Sept 21;32 (Supplement 5):S1130-S1131. doi: 10.1016/j.annonc.2021.08.1554

Author

Lim, K. H. J. ; Hardy, Claire. / 1561O The future of the oncology workforce since COVID-19 : Results of the ESMO Resilience Task Force survey series. In: Annals of Oncology. 2021 ; Vol. 32 , No. Supplement 5. pp. S1130-S1131.

Bibtex

@article{e1d8a647a72d4926986643e0f63542bb,
title = "1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series",
author = "Lim, {K. H. J.} and Claire Hardy",
year = "2021",
month = sep,
day = "21",
doi = "10.1016/j.annonc.2021.08.1554",
language = "English",
volume = "32 ",
pages = "S1130--S1131",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "Supplement 5",

}

RIS

TY - JOUR

T1 - 1561O The future of the oncology workforce since COVID-19

T2 - Results of the ESMO Resilience Task Force survey series

AU - Lim, K. H. J.

AU - Hardy, Claire

PY - 2021/9/21

Y1 - 2021/9/21

U2 - 10.1016/j.annonc.2021.08.1554

DO - 10.1016/j.annonc.2021.08.1554

M3 - Meeting abstract

VL - 32

SP - S1130-S1131

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - Supplement 5

ER -